Hypertension 2025 Scientific Sessions  /  Recent Advances in Hypertension: GLP-1 Agonists  /  Understanding the GLP-1 Receptor as a Drug Target- Physiology Chasing Pharmacology
Logo

American Heart Association

  55
  0

Final ID:

Understanding the GLP-1 Receptor as a Drug Target- Physiology Chasing Pharmacology

  • Dalessio, David  ( Duke University , Durham , North Carolina , United States )
    • Author Disclosures:
    David DAlessio: No Answer
Meeting Info:

Hypertension 2025 Scientific Sessions

2025

Baltimore, Maryland

Session Info:

Recent Advances in Hypertension: GLP-1 Agonists

Friday, 09/05/2025 , 08:00AM - 09:00AM

Recent Advances Plenary

More abstracts on this topic:
Combination Therapies in Kidney Disease: Revolutionizing Cardiovascular-Kidney-Metabolic Health

Rangaswami Janani

More abstracts from these authors:
Once-weekly Tirzepatide versus Dulaglutide for Heart Failure Outcomes in Patients with Type 2 Diabetes, ASCVD, and History of Heart Failure (pre-specified analysis of the SURPASS-CVOT Randomized Clinical Trial)

Nicholls Stephen, Dalessio David

Once-weekly tirzepatide versus dulaglutide on major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease

Nicholls Stephen, Dalessio David

You have to be authorized to contact abstract author. Please, Login
Not Available